These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27379922)

  • 1. Effects of short-term administration of tolvaptan after open heart surgery.
    Matsuyama K; Koizumi N; Nishibe T; Iwasaki T; Iwahasi T; Toguchi K; Takahashi S; Iwahori A; Maruno K; Ogino H
    Int J Cardiol; 2016 Oct; 220():192-5. PubMed ID: 27379922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Suehiro Y; Hosono M; Shibata T; Sasaki Y; Hirai H; Nakahira A; Kubota Y; Kaku D; Suehiro S
    Osaka City Med J; 2016 Dec; 62(2):111-119. PubMed ID: 30721586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement.
    Iida Y; Yoshitake A; Shimizu H
    Ann Vasc Surg; 2019 Apr; 56():103-107. PubMed ID: 30342208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Ito H; Mizumoto T; Tempaku H; Fujinaga K; Sawada Y; Shimpo H
    J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1471-1478. PubMed ID: 27591907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.
    Kerling A; Toka O; Rüffer A; Müller H; Habash S; Weiss C; Dittrich S; Moosmann J
    BMC Pediatr; 2019 Feb; 19(1):57. PubMed ID: 30755181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Tolvaptan in Patients with Volume Overload after Cardiac Surgery.
    Noguchi K; Tanaka M; Katayama I; Yamabe T; Yuji D; Oosiro N; Sirouzu M
    Heart Surg Forum; 2015 Nov; 18(6):E232-6. PubMed ID: 26726710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Tolvaptan Protect Renal Function in the Early Postoperative Period of Cardiac Surgery?　- Results of a Single-Center Randomized Controlled Study.
    Kishimoto Y; Nakamura Y; Harada S; Onohara T; Kishimoto S; Kurashiki T; Fujiwara Y; Nishimura M
    Circ J; 2018 Mar; 82(4):999-1007. PubMed ID: 29467353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
    Komiya S; Katsumata M; Ozawa M; Haze T; Kawano R; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
    Clin Exp Nephrol; 2022 Sep; 26(9):851-858. PubMed ID: 35471469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.
    Nishi H; Toda K; Miyagawa S; Yoshikawa Y; Fukushima S; Kawamura M; Yoshioka D; Saito T; Ueno T; Kuratani T; Sawa Y
    Surg Today; 2015 Dec; 45(12):1542-51. PubMed ID: 26411431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    Miyazaki M; Yada M; Tanaka K; Senjyu T; Goya T; Motomura K; Kohjima M; Kato M; Masumoto A; Kotoh K
    World J Gastroenterol; 2017 Aug; 23(29):5379-5385. PubMed ID: 28839438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H; Hagiwara S; Nishida N; Ueshima K; Sakurai T; Ida H; Minami Y; Takita M; Kono M; Minami T; Iwanishi M; Umehara Y; Watanabe T; Komeda Y; Arizumi T; Kudo M
    Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Safety and Efficacy Study of Tolvaptan Following Open Heart Surgery in 109 Cases.
    Kono T; Tayama E; Hori H; Ueda T; Yamaki Y; Tanaka H
    Int Heart J; 2016 Jul; 57(4):496-502. PubMed ID: 27396557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.